BioArctic AB (publ) has shared that Leqembi is now available at a private clinic in Finland, with the first patient beginning treatment. The company is teaming up with its partner Eisai to help promote Leqembi across the Nordic countries. This is a big step forward for BioArctic as it works toward becoming a top pharmaceutical company in Sweden. Gunilla Osswald, the CEO of BioArctic, is happy with this progress and stressed the need for treatments that can slow the early stages of Alzheimer’s. She also mentioned the importance of supporting patients, their families, and the community. Osswald added that this new therapy came from more than 20 years of research led by Professor Lars Lannfelt at Uppsala University, making it especially meaningful to see it benefitting patients near its origin.

Health Technology Insights: Myriad and SOPHiA Partner on Liquid Biopsy Diagnostic Tool

Leqembi was approved by the European Commission in April 2025 as the first treatment targeting the root causes of Alzheimer’s. It is prescribed for adults with mild cognitive impairment or mild dementia caused by Alzheimer’s, especially those who are not carriers or only partial carriers of the ApoE ε4 gene and have confirmed amyloid buildup in the brain. Since approval, BioArctic and Eisai have been working with Nordic health authorities to meet the necessary requirements. In Finland, a controlled access program has been set up, enabling private clinics such as Terveystalo Ruoholahti to start treating patients. Talks are still happening to get Leqembi included in the public healthcare system.

Health Technology Insights: Ultromics Study Shows AI Could Improve Early Detection of Cardiac Amyloidosis

Alzheimer’s is a disease that gets worse over time, marked by the build-up of amyloid-beta and tau proteins in the brain. As the condition progresses, it causes more difficulty for patients and their caregivers. Studies show that amyloid-beta protofibrils and tau tangles contribute to the destruction of brain cells. Leqembi is special because it targets both these harmful proteins, which can help stop the formation of tau tangles, offering a two-pronged approach to treating the disease.

The development of Leqembi is the result of a long partnership between BioArctic and Eisai. The antibody was first developed by BioArctic based on Professor Lars Lannfelt’s discovery of the Arctic mutation in Alzheimer’s. While Eisai takes care of clinical development, regulatory approvals, and worldwide sales, BioArctic holds the rights to market Leqembi in the Nordic region, working together with Eisai. Both companies are getting ready for a coordinated launch in this area.

Health Technology Insights: Sidecar Health Partners with Carrum Health for Centers of Excellence

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com